Celldex Therapeutics Inc (CLDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
69
About the Report
About the Report
Summary
Celldex Therapeutics Inc (Celldex) is a bio-pharmaceutical company that discovers, develops and commercializes targeted immunotherapy technologies and cancer-targeting biologicsfor the treatment of various types of cancers. The company's developmental pipeline comprises therapeutic antibodies, antibody drug conjugates (ADCs), immune system modulators, vaccines and other protein-based therapeutics. Its key products in development include glembatumumabvedotin; Varlilumab; CDX-1401; CDX-3379; CDX-0158; CDX-301; and CDX-014. Celldex's products find application in the treatment of various indications such as brain cancer, triple negative breast cancer, lymphoma/leukemia, melanoma, and renal cell carcinoma. It operates a manufacturing facility in Fall River, Massachusetts; and research laboratories in Massachusetts, New Jersey and Connecticut. Celldex is headquartered in Hampton, New Jersey, the US.
Celldex Therapeutics Inc (CLDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Celldex Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Kolltan Pharma Raises USD 60 Million In Series D Financing 14
Kolltan Pharma Raises USD 25 Million In Series C Financing 16
Partnerships 17
Celldex Therapeutics Enters into Agreement with Roche 17
Licensing Agreements 18
Shanghai Henlius Biotech Enters into Licensing Agreement with Kolltan Pharma for KTN0216 18
Kolltan Pharma Enters into Licensing Agreement with Spirogen 19
Kolltan Pharma Enters Into Licensing Agreement With University of Toronto For Anti-KIT Antibodies And Related IP 20
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 21
Kolltan Pharma Enters Into Licensing And Research Agreement With Children's Hospital of Philadelphia For Pediatric Neuroblastoma Therapies 22
Equity Offering 23
Celldex Therapeutics Files Registration Statement for Public Offering of Shares 23
Celldex Therapeutics to Raise up to USD48.8 Million in Final Tranche of Public Offering of Shares 24
Celldex Therapeutics Raises USD200 Million in Public Offering of Shares 25
Kolltan Pharma Withdraws IPO 27
Celldex Therapeutics Completes Public Offering Of Shares For USD 191.4 Million 28
Celldex Therapeutics Completes Public Offering Of Shares For USD 104 Million 30
Celldex Therapeutics Completes Second Tranche Of Private Placement Of Shares For USD 7.3 Million 32
Celldex Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 21 Million 33
Celldex Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For USD 46 Million 35
Acquisition 37
Celldex Therapeutics Acquires Kolltan Pharma 37
Kolltan Pharma Acquires Xetrios Therapeutics 38
Celldex Therapeutics Inc-Key Competitors 39
Celldex Therapeutics Inc-Key Employees 40
Celldex Therapeutics Inc-Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Nov 07, 2018: Celldex provides corporate update and reports third quarter 2018 results 43
Aug 08, 2018: Celldex provides corporate update and reports second quarter 2018 results 45
May 10, 2018: Celldex Provides Corporate Update and Reports First Quarter 2018 Results 47
Mar 07, 2018: Celldex Provides Corporate Update and Reports Full Year 2017 Results 50
Nov 07, 2017: Celldex Reports Third Quarter 2017 Results 52
Aug 08, 2017: Celldex Reports Second Quarter 2017 Results 56
May 09, 2017: Celldex Reports First Quarter 2017 Results 58
Mar 14, 2017: Celldex Provides Corporate Update and Reports Full Year 2016 Results 60
Corporate Communications 62
Oct 03, 2017: Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs 62
Sep 12, 2017: Celldex Announces Departure of Chief Medical Officer 63
Jun 16, 2017: Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team 64
Mar 01, 2017: Celldex Therapeutics Announces Appointment to Board of Directors 65
Clinical Trials 66
Apr 20, 2018: Celldex Therapeutics presents data on CDX-1140 at AACR Annual Meeting 2018 66
Nov 30, 2017: Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors 67
May 17, 2017: Celldex Therapeutics to Present Clinical Results from Phase 2 Study of Glembatumumab Vedotin at 2017 ASCO Annual Meeting 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69
List of Figure
List of Figures
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celldex Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Kolltan Pharma Raises USD 60 Million In Series D Financing 14
Kolltan Pharma Raises USD 25 Million In Series C Financing 16
Celldex Therapeutics Enters into Agreement with Roche 17
Shanghai Henlius Biotech Enters into Licensing Agreement with Kolltan Pharma for KTN0216 18
Kolltan Pharma Enters into Licensing Agreement with Spirogen 19
Kolltan Pharma Enters Into Licensing Agreement With University of Toronto For Anti-KIT Antibodies And Related IP 20
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 21
Kolltan Pharma Enters Into Licensing And Research Agreement With Children's Hospital of Philadelphia For Pediatric Neuroblastoma Therapies 22
Celldex Therapeutics Files Registration Statement for Public Offering of Shares 23
Celldex Therapeutics to Raise up to USD48.8 Million in Final Tranche of Public Offering of Shares 24
Celldex Therapeutics Raises USD200 Million in Public Offering of Shares 25
Kolltan Pharma Withdraws IPO 27
Celldex Therapeutics Completes Public Offering Of Shares For USD 191.4 Million 28
Celldex Therapeutics Completes Public Offering Of Shares For USD 104 Million 30
Celldex Therapeutics Completes Second Tranche Of Private Placement Of Shares For USD 7.3 Million 32
Celldex Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 21 Million 33
Celldex Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For USD 46 Million 35
Celldex Therapeutics Acquires Kolltan Pharma 37
Kolltan Pharma Acquires Xetrios Therapeutics 38
Celldex Therapeutics Inc, Key Competitors 39
Celldex Therapeutics Inc, Key Employees 40
Celldex Therapeutics Inc, Other Locations 41
Celldex Therapeutics Inc, Subsidiaries 41
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.